Introduction {#s1}
============

All cancers result from somatic mutations in their genomes. Beyond the ∼3200 Mb of nuclear genomic DNA, human cells have hundreds to thousands of mitochondria present in every cell, each carrying one or a few copies of the 16,569 bp circular mitochondrial genomes ([@bib50]; [@bib32]; [@bib30]). In addition to their role in cellular energy balance through oxidative phosphorylation, mitochondria are involved in many essential cellular functions including modulation of oxidation--reduction status, contribution to cytosolic biosynthetic precursors, and initiation of apoptosis. Mitochondria in eukaryotic cells evolved by endosymbiosis from a free-living α-proteobacterium ([@bib20]). Over 2 billion years of co-evolution, many ancestral mitochondrial genes have transferred to the nucleus ([@bib15]; [@bib5]; [@bib55]). What remains in the mitochondrial genome is distinctive for the striking asymmetry between the two complementary mtDNA strands in terms of nucleotide content and gene distribution ([@bib2]). The heavy (H) strand is guanine-rich (C/G = 0.4) and is the template from which most mitochondrial proteins (12 out of 13) are transcribed, whereas only one protein-coding gene, *MT-ND6*, is transcribed from the correspondingly cytosine-rich light (L) strand.

Mutations in the mitochondrial genome cause inherited disease ([@bib7]), with a maternal inheritance pattern because only eggs contribute mitochondria to the zygote. The penetrance of inherited mitochondrial disease is determined stochastically by both the random assortment of mutated vs wild-type mitochondrial genomes during meiosis and random drift during the early cell divisions after fertilization. In cancer, the role of somatically acquired mtDNA mutations is controversial. Although cancer-specific mutations have been previously reported ([@bib45]; [@bib4]; [@bib6]; [@bib24]; [@bib31]), the limited sample size or poor sensitivity of capillary sequencing for heteroplasmic mutations has not allowed a comprehensive analysis of the mutational signatures of mitochondrial mutations nor their likely functional significance. It has long been proposed that mitochondria might contribute to cancer development given their fundamental importance to cellular biology ([@bib55]). Previous reports suggested that mitochondrial somatic mutations might be under positive selection and thus contribute to cancer development, but the small number of reported mutations renders this conclusion uncertain ([@bib4]; [@bib6]; [@bib31]; [@bib49]). Nonetheless, the hypothesis of functionally relevant mitochondrial mutations is an appealing one because cancer cells have greatly increased energy demands over normal cells and demonstrate a switch from aerobic glycolysis in mitochondria to lactic acid fermentation in the cytosol (the Warburg effect) ([@bib23]; [@bib30]).

In each cell cycle, the replicating genome is at risk of de novo mutations, which can promote the development of cancer. These mutations may be generated by intrinsic cellular errors during DNA replication or repair or through exposure to mutagens, such as reactive oxygen species, tobacco smoke, and ultraviolet light ([@bib43], [@bib44]). Recently, \>20 mutational signatures operative in cancers have been identified in the nuclear genome ([@bib1]). Whether any of these mutational processes also affect the mitochondrial genome has not been studied. Furthermore, whether there are mtDNA-specific mutational processes in somatic cells remain unclear, although the many unique features of mtDNA replication and repair, coupled with the high concentration of reactive oxygen species generated by the electron transport chain, could be associated with distinctive mutation signatures.

In this study, we compare 1675 cancer and paired normal mtDNA sequences across 31 tumor types using massively parallel DNA sequencing technologies to obtain a systematic and unbiased catalog of somatic mitochondrial mutations. We find that mtDNA mutations are almost exclusively the product of a mutational process that is specific to mitochondria and probably linked to the unique mechanism of genome replication these organelles employ. We find no evidence for positive selection of mitochondrial mutations during oncogenesis, suggesting that they confer no clonal advantage on the nascent cancer cells.

Results {#s2}
=======

mtDNA sequencing and Mutation Calling {#s2-1}
-------------------------------------

We extracted the mtDNA sequences from 704 whole-genome and 971 whole-exome sequencing data generated on primary cancers and compared them with mtDNA sequences from their matched normal samples. Given the abundance of mtDNA per cancer cell, a standard coverage of 30--40× in the nuclear genome provides significantly greater coverage of the mitochondrial genome (average read depth = 7901.0×), enabling accurate identification of somatic mutations including rare heteroplasmic variants. We also assessed whether whole-exome sequencing could be used to identify mtDNA mutations from off-target reads derived from the mitochondrial genome. We found an average read depth of 92.1× across the mitochondrial genome in exome studies. From 139 samples in which we had both exome and whole-genome sequencing data, the overall read depths correlated strongly (R^2^ = 0.59, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) as did variant allele fractions for mtDNA somatic mutations (R^2^ = 0.97, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Validation experiments suggested the sensitivity of whole-exome sequencing for detection of mtDNA somatic mutations to be 71.4% compared to whole-genome sequencing ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"} and 'Materials and Methods', 'Off-target mtDNA reads in whole-exome sequencing' and 'DNA cross-contamination').

To reduce potential false-positive calls of mtDNA somatic mutations, we only report variants called with an allele fraction of \>3%. This eliminates the risk of miscalls due to mtDNA-derived pseudogenes in the nucleus (NuMTs) because mtDNA copy numbers are 100--1000 times higher than nuclear genomes in human somatic cells, and the sequence homology between mtDNA and NuMTs presented in the human reference genome is generally \<95% (in 96 out of 101 NuMTs with length greater than 300 bp). Furthermore, pairwise comparison between cancer and matched normal mtDNAs from the same individual further minimizes the contamination of NuMTs in the mutation calling.

The catalog of mtDNA somatic mutations {#s2-2}
--------------------------------------

In total, 1675 tumor--normal pairs across 31 tumor types were analyzed ([Table 1](#tbl1){ref-type="table"} and [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). For 61 of these patients, we had sequencing data available from multiple sites of the primary cancer, several time points or matched primary cancers, and metastases (a total of 73 such cancer samples), allowing us to study the timing of mtDNA mutations in cancer evolution ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). We identified 1907 somatic mtDNA substitutions ([Figure 1](#fig1){ref-type="fig"} and [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). In contrast to inherited polymorphisms (n = 38,706, available at [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}), which were almost always homoplasmic in both the cancer and counterpart normal, the variant allele fractions (VAFs) of these somatic substitutions were highly variable in the cancer, ranging from our detection threshold (3%) to homoplasmy (100%). Of these 1907 somatic substitutions, 1209 (63.4%) were not registered in the databases of mtDNA common polymorphism ([@bib27]; [@bib33]). In comparison, when we examined substitutions found in both the tumor and the normal samples from a patient, only 21 (0.05%) were not registered in the polymorphism databases, a significantly different fraction from the tumor-only variants (p \< 10^−10^; Chi-squared test). We found 595 (31.2%) recurrent mutations that can be collapsed onto 246 mtDNA positions, which is a 6.9-fold higher level of recurrence than expected by chance (p \< 10^−10^). This suggests that the generation or fixation of mtDNA mutations is not random, but influenced by factors such as the underlying mutational process or positive selection.10.7554/eLife.02935.003Table 1.Summary statistics of mtDNA sequence data**DOI:** [http://dx.doi.org/10.7554/eLife.02935.003](10.7554/eLife.02935.003)WGSWXSAverage mt RD (WGS)Average mt RD (WXS)TotalWGSWXSAverage mt RD (WGS)Average mt RD (WXS)TotalBreast2849811594.352.7382Meningioma012-42.512Colorectal17534916.9276.676Ependymoma1910323.752.710Lung6002798.1-60Prostate80017810.6-80MPD121381517.010.9150Hepatocellular047-205.847MDS3755648.744.578Melanoma1313513.9353.526ALL646886.635.970Gastric013-184.113CLL605002.2-6Cholangiocarcinoma08-143.98AML166783.627.47Mesothelioma06-106.36Multiple myeloma069-43.269Bladder540646.2-54AMKL09-24.29Renal023-35.423Lymphoma04-99.54Ovarian038-58.938Uterine2723736.0149.550Osteosarcoma38909525.5119.2128Cervical052-85.252Chondrosarcoma047-99.147Adenoid cystic ca.160714.775.661Ewing sarcoma027-69.527Head & Neck4331369.118.846Kaposi sarcoma09-181.09Chordoma16111240.082.127Total; 31 cancer types7049711675[^1]10.7554/eLife.02935.004Figure 1.Mitochondrial somatic substitutions identified from 1675 Tumor--Normal pairs.mtDNA genes and intergenic regions are shown. The strand of genes is shown based on mtDNA strand containing equivalent sequences of transcribed RNA. Substitution categories (silent, non-silent (missense and nonsense), non-coding (tRNA and rRNA), and intergenic) are shown by the shapes of each substitution. Six classes of substitutions are presented color-coded. The substitutions on the H, and L strand (when six substitutional classes were considered) are shown outside and inside of mtDNA genes, respectively. Vertical axes for H and L strand substitutions represent the VAF of each variant.**DOI:** [http://dx.doi.org/10.7554/eLife.02935.004](10.7554/eLife.02935.004)10.7554/eLife.02935.005Figure 1---figure supplement 1.Correlation in amount of mtDNA reads between whole-genome and whole-exome sequencing.139 DNA samples, either from tumors or bloods, sequenced by whole-genome sequencing were additionally sequenced by whole-exome sequencing. We compared the amount of mtDNA reads between whole-genome and whole-exome sequencing. As shown in this figure, we found strong positive correlation. \* CGP; Cancer Genome Project, Wellcome Trust Sanger Institute, WUGSC; Washington University Genome Sequencing Center.**DOI:** [http://dx.doi.org/10.7554/eLife.02935.005](10.7554/eLife.02935.005)10.7554/eLife.02935.006Figure 1---figure supplement 2.Correlation of heteroplasmy levels between whole-genome and whole-exome sequencing.To validate the sensitivity and specificity of variant calling in this study, 19 tumor and normal pairs (which were originally whole-genome sequenced) were whole-exome sequenced and mtDNA variants were assessed independently. We correlated the heteroplasmic levels of 20 mutations detected in common.**DOI:** [http://dx.doi.org/10.7554/eLife.02935.006](10.7554/eLife.02935.006)10.7554/eLife.02935.007Figure 1---figure supplement 3.Validation of mtDNA somatic substitutions.**DOI:** [http://dx.doi.org/10.7554/eLife.02935.007](10.7554/eLife.02935.007)10.7554/eLife.02935.008Figure 1---figure supplement 4.Amount of off-target mtDNA reads across four sequencing centers.**\*** CGP; Cancer Genome Project, Wellcome Trust Sanger Institute (n = 855), WUGSC; Washington University Genome Sequencing Center (n = 140), BCM; Baylor College of Medicine (n = 85), BI; Broad Institute (n = 435).**DOI:** [http://dx.doi.org/10.7554/eLife.02935.008](10.7554/eLife.02935.008)10.7554/eLife.02935.009Figure 1---figure supplement 5.Filtering samples of potential DNA contaminations.(**A**) A histogram presenting potential sample swaps in tumor--sample pairs. (**B**) A histogram presenting potential minor DNA cross-contamination in tumor samples. Cross-contamination levels were considered in filtering substitutions (see "Minor cross-contamination of DNA samples" section in Materials and Methods). (**C**) Histograms showing number of somatic substitutions overlapping with known inherited polymorphisms and (**D**) number of back mutations.**DOI:** [http://dx.doi.org/10.7554/eLife.02935.009](10.7554/eLife.02935.009)

Of the 1675 cancer samples, 976 (58.3%) harbored at least one somatic substitution and 521 (31.1%) had multiple substitutions, ranging from 2 to 7 ([Figure 2A](#fig2){ref-type="fig"}). In those with multiple substitutions, 72 pairs of mutations were sufficiently close to phase ([@bib38]) such that we could determine whether they were linked on the same mtDNA genome or were on different copies. We found that 45 (62.5%) pairs of mutations were linked on the same mtDNA genome ([Supplementary file 3](#SD3-data){ref-type="supplementary-material"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Furthermore, of these linked mutations, 33 showed a clear temporal order: that is, one mutation was demonstrably sub-clonal to the other. This is rather unexpected, since each somatic cell has 100--1000 copies of the mitochondrial genome, and we might anticipate that random mutations would, on average, affect different copies. That many pairs of mutations are phased on the same mtDNA genome and yet show a clear sub-clonal relationship suggests that they occur sufficiently separated in time to allow the mitochondrial genome carrying the earlier mutation to drift towards a substantial fraction of all genomes in that cell before the second mutation occurs, consistent with a previous report ([@bib10]).10.7554/eLife.02935.010Figure 2.mtDNA somatic substitutions of human cancer.(**A**) Number of somatic substitutions in a tumor sample. (**B**) Average number of somatic substitutions per sample across 31 tumor types. (**C**) Age of diagnosis and number of mtDNA somatic substitutions in breast cancers.**DOI:** [http://dx.doi.org/10.7554/eLife.02935.010](10.7554/eLife.02935.010)10.7554/eLife.02935.011Figure 2---figure supplement 1.VAFs of phased somatic mtDNA substitutions.This figure presents VAF pairs between co-clonal, sub-clonal, and different strand mtDNA substitutions. We expect similar VAFs for co-clonal pairs; lower VAF in sub-clonal mutations compared to clonal ones; and sum of a VAF pair is equal or less than 1.0.**DOI:** [http://dx.doi.org/10.7554/eLife.02935.011](10.7554/eLife.02935.011)

The number of somatic mtDNA substitutions varied significantly according to tumor type (p = 4.4 × 10^−52^) after correcting for confounding variables such as sequencing coverage: gastric, hepatocellular, prostate, and colorectal cancers had the highest number of mtDNA substitutions ([Figure 2B](#fig2){ref-type="fig"}). In contrast, hematologic cancers (acute lymphoblastic leukemia, myeloproliferative disease, and myelodysplastic syndrome) had fewer mutations. Several possible explanations could underpin these differences across tumor types. It could be that the mutation rates differ across cell lineages; it could be that selection pressures shape the number of mutations; or the number of mtDNA genome generations could differ across cell lineages. Of these explanations, we believe that the second is unlikely because, as we shall see, positive selection is not a major component of mitochondrial mutations. Interestingly, we find a positive correlation between the number of mtDNA somatic mutations and age at diagnosis in breast cancers (p = 0.0004; [Figure 2C](#fig2){ref-type="fig"}), in keeping with the idea that the number of mitochondrial generations is linked to mutation burden. The mutational burden of an established cancer represents the accumulated variation acquired in the lineage of cell divisions from fertilized egg to transformed cell and will include events acquired in normal development and homeostasis as well as those acquired during tumorigenesis ([@bib51]). Interestingly, mtDNA mutations have been found at high rates in normal colonic crypt cells ([@bib52]; [@bib12]). Given that we find high burdens of mutations in colonic tumors as well, the differences we see across tumor types may arise from pre- or post-transformation differences in mtDNA burden across tissues.

Extracting mtDNA mutational signatures {#s2-3}
--------------------------------------

With respect to signatures of somatic substitutions, C \> T and T \> C transitions constituted 90.9% of all the 1907 substitutions ([Figure 1](#fig1){ref-type="fig"}) among the six classes of possible base substitutions. To characterize this aggregated signature of mtDNA cancer specific mutations in more detail, we looked for the presence of mtDNA strand bias between the complementary H and L strands of mtDNA. The two main substitution classes showed an extreme level of mtDNA strand bias. 84.1% of the C \> T transitions were on the H strand. This level of strand bias occurred despite the fact that cytosine is 2.4-fold less common on the H than the L strand, so the C \> T substitution rate is 12.6-fold higher on the H strand. By contrast, 76.8% of the T \> C transitions were on the L strand despite its lower thymine content (1.3-fold less than the H strand). This implies that the T \> C mutation rate on the L strand is 4.2-fold higher than on the H strand.

We then examined the sequence context in which these mutations occurred by examining the bases immediately 5′ and 3′ to the mutated bases. This generates 96 possible mutation classes (the 6 substitution classes multiplied by the 16 combinations of immediate 5′ and 3′ nucleotides). Both C \> T and T \> C mutations showed highly distinctive sequence contexts. C~H~ \> T~H~ substitutions (i.e. C \> T mutations on the H strand) were enriched for the Np[C]{.ul}pG trinucleotide context (8- to 15-fold more frequent than expected by chance; [Figure 3A](#fig3){ref-type="fig"}). By contrast, T~L~ \> C~L~ substitutions (i.e. T \> C mutations on the L strand) showed 5- to 8-fold enrichment in Np[T]{.ul}pC. This strand-asymmetric mutational signature is not similar to any of the 21 cancer-associated mutational signatures recently identified from the nuclear DNA of 30 different cancer types ([@bib1]).10.7554/eLife.02935.012Figure 3.Replicative strand bias for mtDNA somatic substitutions.(**A**) Replicative strand-specific substitution rate (\# of observed/\# of expected) by 96 trinucleotide context. Substitutions in a specific mtDNA segment (from Ori-b to O~H~) are not included, because they present a different substitutional signature. (**B**) Mutational signature across tumor types. Eighteen tumor types, which include at least 25 mtDNA mutations, were shown. (**C**) Inverted substitution signature in the Ori-b--O~H.~**DOI:** [http://dx.doi.org/10.7554/eLife.02935.012](10.7554/eLife.02935.012)10.7554/eLife.02935.013Figure 3---figure supplement 1.Replicative strand bias observed in mtDNA substitutions.(**A**) Mutational signature of mtDNA somatic substitutions on the 12 L strand genes by replicative strand (L/H strand). It agrees very well with the background mutational signature. (Chi-square p = 0.99999). (**B**) Mutational signature of mtDNA somatic substitutions on the H strand gene (*MT-ND6*) by replicative strand. It is very close to the background very close to the expected background signature (Chi-square p = 0.027). If we consider signature by transcriptional strand, the signature difference is very clear (Chi-square p = 1 × 10^−21^). These suggest the strand bias not to be transcription-coupled, but replication coupled. (**C**) Mutational spectrum of mtDNA somatic substitutions on the 22 tRNA genes by replicative strand. Again, it agrees very well with the background mutational signature (Chi-square p = 0.71). (**D**) Mutational spectrum of mtDNA somatic substitutions on the 22 tRNA genes by non-transcribed (coding) and transcribed (non-coding) strand. Strand bias was greatly subsided because somatic substitutions on 14 L strand and 8 H strand tRNAs neutralize the strand bias (C~H~ \> T~H~ and T~L~ \> C~L~) each other. As a result, this signature of tRNA mutations by transcriptional strand is significantly different from the background one (Chi-square p = 3.3 × 10^−12^). Taken all together, we concluded that the cause of strand bias is not transcription-coupled but is replicative.**DOI:** [http://dx.doi.org/10.7554/eLife.02935.013](10.7554/eLife.02935.013)

Of the 18 tumor types that presented at least 25 mtDNA somatic substitutions in this study, the mutational signatures were broadly consistent across tumor types ([Figure 3B](#fig3){ref-type="fig"}), with the exception that multiple myeloma had a somewhat higher rate of T~H~ \> C~H~ changes than other histologies (p = 8.1 × 10^−6^). Thus, in contrast to the mutational signatures found in nuclear genomes, where there is striking heterogeneity both across tumor types and across individuals within a tumor type ([@bib1]), the mutational profile in the mitochondrial genome of somatic cells is remarkably homogeneous.

Replication-coupled mutational process in mitochondria {#s2-4}
------------------------------------------------------

The major known cause of mutational strand bias in nuclear DNA is transcription-coupled nucleotide excision repair, where DNA lesions on the transcribed (non-coding) strand are more frequently repaired ([@bib1]). However, we find that the strand bias always favors C~H~ \> T~H~ and T~L~ \> C~L~ whether the gene is transcribed from the H strand or from the L strand ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). This is not compatible with transcription-coupled repair, for which the direction of strand bias is fundamentally dictated by which strand is transcribed.

Instead, the mtDNA mutational strand bias reported here appears to be driven by differences in replication between the two strands. mtDNA replication harbors substantial strand asymmetry between the H and L strands: mtDNA replication initiates from an origin of replication (O~H~) in the D-loop, with the nascent H and the L strand replicating as leading and lagging strand, respectively ([@bib8]; [@bib15]; [@bib25]). We observed that C \> T substitutions were prevalent in the leading (heavy) strand, whereas T \> C substitutions were found in the lagging (light) strand ([Figure 1](#fig1){ref-type="fig"}). Remarkably, this strand bias was reversed in the D-loop itself ([Figures 1 and 3C](#fig1 fig3){ref-type="fig"}), further suggesting that the mtDNA somatic mutations are replication-coupled: according to a recently proposed bidirectional model of mtDNA replication ([@bib58], [@bib57]; [@bib25]), mtDNA replication is also able to initiate from the so-called Ori-b site, typically located around genomic position 16,197 and proceeds on both strands away from the origin ([Figure 1](#fig1){ref-type="fig"}). Replication of the nascent H strand continues unimpeded like the traditional model, but the nascent L strand terminates at the so-called O~H~ site, typically around mtDNA position 191 bp. Under this model, then, the leading and lagging strand are reversed in the few hundred base-pairs of the D-loop, which is consistent with the reversed mutational signature in this region ([Figures 1 and 3C](#fig1 fig3){ref-type="fig"}).

Equivalent mutational signature during human mtDNA Evolution {#s2-5}
------------------------------------------------------------

It is not entirely straightforward to infer the mutational signatures operating on the mitochondrial genome in the germline. De novo mutations are generally rare and often discovered because they cause disease; distinguishing the ancestral base and the derived base is challenging for single nucleotide polymorphisms; and comparative mtDNA genomics across species extends over considerable evolutionary time. In contrast, because ancestral and derived states are defined for tumor--normal pairs, a much clearer picture emerges of the somatic mtDNA mutation signature. We therefore assessed whether the signature that emerges for somatic mitochondrial mutations could extend to explain sequence composition of the human mtDNA genome.

It appears that the mutational mechanism which has generated the C~H~ \> T~H~ and T~L~ \> C~L~ signature in cancer mtDNA is equivalent to the one that has been operating during evolution of human germline mtDNA ([@bib39]). This manifests as the depletion of certain codons in the reference human mtDNA sequence through the action of the C~H~ \> T~H~ and T~L~ \> C~L~ mutational process over time ([Figure 4A](#fig4){ref-type="fig"}). For example, the GC[G]{.ul} triplet codon (Alanine) appears to have been replaced by its synonymous GC[A]{.ul} codon (due to C~H~ \> T~H~ (G~L~ \> A~L~)), with the former being 15.8-fold less frequently observed in the 12 mtDNA protein-coding genes that are transcribed from the H strand (and encoded on the L strand). All 32 synonymous codon pairs present the same tendency. Consistent with this interpretation, the gene transcribed from the L strand (*MT-ND6*) demonstrates the opposite direction of skew. Further analyses of mtDNA codon usage from seven animal species suggest that the C~H~ \> T~H~ and T~L~ \> C~L~ mutational pressure may be characteristic of vertebrates, and primates in particular ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).10.7554/eLife.02935.014Figure 4.Mutational signature similar to processes shaping human mtDNA sequence over evolutionary time.(**A**) Triplet codon depletion in human mtDNA by equivalent (C~H~ \> T~H~ and T~L~ \> C~L~) mutational pressure. Relative frequency of each triplet codon within synonymous pairs (NNT--NNC or NNA--NNG) is shown by color. The arrows beside the box highlight the T \> C (red) and G \> A (blue) substitutional pressures on the L strand in germline mtDNA. (**B**) Correlation of triplet codon frequencies between from observed and from simulated evolutions of a random sequence mtDNA by the mtDNA somatic mutational signature with constraining mitochondrial protein sequences.**DOI:** [http://dx.doi.org/10.7554/eLife.02935.014](10.7554/eLife.02935.014)10.7554/eLife.02935.015Figure 4---figure supplement 1.TC and GA skew for L strand mtDNA genes across 8 animal species.*C. elegans* (a nematode) and *D. melanogaster* (fruit fly) mtDNA appears to have G~L~ \<\< A~L~ (due to C~H~ \> T~H~ mutational pressure) and C~L~ \>\> T~L~ (due to C~L~ \> T~L~ mutational pressure) in the third base of triplet codon in L strand genes. Therefore they seem to have predominant C \> T mutational pressure without strand bias. *D. rerio* (zebrafish), *X. laevis* (frog), and *M. musculus* (mouse) present G~L~ \<\< A~L~ (due to C~H~ \> T~H~ mutational pressure), but similar number of C~L~ and T~L~. Therefore, mtDNA of these sequences is thought to have C~H~ \> T~H~, with strand bias. The existence of T~L~ \> C~L~ is not clear. Finally, mtDNA of *H. sapiens*, *P. troglodytes* (Chimpanzee), and *G. domesticus* (Chicken) shows clear C~H~ \> T~H~ and T~L~ \> C~L~ as mentioned in the main manuscript. Interestingly, T~L~ \> C~L~ seems to be slightly stronger in the mitochondria of chicken than that of human (or chimp). We suggest there would be some differences in the mechanism of mtDNA replication across the evolution tree.**DOI:** [http://dx.doi.org/10.7554/eLife.02935.015](10.7554/eLife.02935.015)10.7554/eLife.02935.016Figure 4---figure supplement 2.Correlation of triplet codon frequencies between from observed and from simulated evolutions under the mtDNA somatic mutational signature.**DOI:** [http://dx.doi.org/10.7554/eLife.02935.016](10.7554/eLife.02935.016)

To quantify whether the somatic mutational signature we have defined can fully explain the trinucleotide frequency of human mtDNA, we performed evolutionary simulations. First, we simulated the evolution of a random DNA sequence under the mutational signature described here. By mutational pressure alone, the random sequence starts losing certain hypermutable trinucleotides until eventually reaching a stationary sequence composition. The actual sequence composition of the human mitochondrial genome strongly resembles this stationary distribution (Pearson\'s r = 0.83; p \< 0.0001; [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). In a second simulation, a random sequence encoding the exact amino acid sequence of the reference mitochondrial genome was evolved by synonymous mutations under the observed mtDNA signature until reaching a stationary sequence composition (mutation--selection equilibrium). These simulations also eventually approximate the observed human mitochondrial genome (Pearson\'s r = 0.96, p \< 0.0001; [Figure 4B](#fig4){ref-type="fig"}). These analyses strongly suggest that the mitochondrial mutation signature observed in cancer cells closely reflects the mutation signature active in the germline, which has continuously shaped the mitochondrial genome during human evolution.

Negative selection on truncating mtDNA mutations and tRNA anticodons {#s2-6}
--------------------------------------------------------------------

Next, we assessed the functional impact of somatic mtDNA mutations. Of the 1907 substitutions, 1153 (60.5%) were in the 13 protein-coding genes. These include 63 nonsense, 4 stop-lost, 878 missense, and 208 silent substitutions ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). In addition, out of 251 indels we observed, 110 occurred within protein-coding genes ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). Of the missense substitutions, 245 (27.9%) were recurrent, affecting 107 distinct mtDNA sites. Although this very high level of mutation clustering could, at first sight, be interpreted as evidence for positive selection, we found that silent substitutions were also frequently recurrent (28 recurrent variants in 13 mtDNA sites), with no substantial difference in recurrence rates between silent and missense mutations (p = 0.19; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). We believe this recurrence to be the consequence of a high mtDNA mutation rate with restricted mutational signature (C~H~ \> T~H~ and T~L~ \> C~L~). Independently recurring mutations in human germline mtDNA are well described across human evolution ([@bib33]).

The ratio of somatic missense to silent substitutions (Rms:s) is apparently higher (4.2, 878/208) than that observed for cancer-associated somatic mutations in nuclear DNA (generally around 2:1 to 3:1 across tumor types) ([@bib21]; [@bib37]). At face value, this again could be interpreted as evidence for positive selection. However, as described above, the somatic mtDNA mutational signature shows extreme strand asymmetry and the same mutational signature has been operative in the germline over evolutionary time. Thus, the dominant mutational signature has already acted on potentially synonymous sites in the mitochondrial genome ([Figure 4A](#fig4){ref-type="fig"}), meaning that any new somatic changes are much less likely to be silent. In keeping with this, a dN/dS ratio (See 'Materials and Methods') calculated taking into account both the mutational signature and the mtDNA codon usage revealed that missense mutations accumulate at a frequency very close to that expected under neutrality (dN/dS = 1.21; 95% confidence interval, 1.015--1.434; p = 0.031). This indicates that despite the apparent high ratio of missense to silent mutations, the vast majority of mtDNA mutations are passengers with no convincing evidence suggesting the existence of driver mitochondrial DNA mutations. Additional gene-by-gene analysis further revealed that no single gene had a higher than expected rate of missense or nonsense mutations ([Supplementary file 4](#SD4-data){ref-type="supplementary-material"}).

For nonsense substitutions and frameshift indels, we observe a somewhat different picture. Taking into account the mutation signature and amino acid composition of the mitochondrial genome, the overall ratio of nonsense mutations to silent mutations is exactly that expected by chance (dNonsense/dS = 1.004; 95% confidence interval, 0.699--1.443; p = 0.98). However, while missense and silent substitutions exhibited equivalent variant allele fractions (average VAFs; 40.1% and 40.9%, respectively; p = 0.8), nonsense substitutions presented significantly lower VAFs (average 26.4%; p = 6x10^−5^), as did frameshift indels (average 25.0%; p = 2 × 10^−3^; [Figure 5A](#fig5){ref-type="fig"}). Taken together, these data suggest that nonsense mutations occur at the expected rate given the underlying mutational process. However, while silent and missense substitutions frequently achieve high allele fractions in tumor cells due to the effects of random drift, there are significantly greater constraints on mitochondrial genomes carrying protein-inactivating mutations. The inference here is that cancer cells carrying such deleterious mutations at or near homoplasmy are at a selective disadvantage and hence do not contribute to clonal expansions, underlining the importance of functional mitochondria to cancer cells. The extent of such disadvantage may vary according to tumor type: for example colorectal cancers show less negative selection compared to breast cancers (p = 0.028; [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}).10.7554/eLife.02935.017Figure 5.Selection and mutational process for mtDNA somatic substitutions.(**A**) Truncating mutations (nonsense substitutions and frame-shifting (FS) coding indels) present significantly lower VAF. (**B**) Change of VAF of mtDNA somatic mutation between primary and metastatic (or late) cancer tissues. (**C**) Mutational signature for mtDNA across various tumor types. None of the three highlighted mechanisms or nuclear DNA double-strand breaks repair mechanism (*BRCA*) match with the mtDNA mutational signature. \* Only substitutions in protein-coding genes considered. (**D**) A proposed model of mtDNA mutational process.**DOI:** [http://dx.doi.org/10.7554/eLife.02935.017](10.7554/eLife.02935.017)10.7554/eLife.02935.018Figure 5---figure supplement 1.Number of recurrent substitutions between silent and missense substitutions.100 sites were randomly selected from silent substitutions (at third base of triplet codon) and missense substitutions (at first and second base of triplet codon). No significant difference was observed among these three groups.**DOI:** [http://dx.doi.org/10.7554/eLife.02935.018](10.7554/eLife.02935.018)10.7554/eLife.02935.019Figure 5---figure supplement 2.Comparison of VAF of protein-truncating mutations (nonsense substitution and indels) across tumor types.Four tumor types with more than 10 protein-truncating mutations are shown. Fisher\'s exact were applied between breast and other tissue types.**DOI:** [http://dx.doi.org/10.7554/eLife.02935.019](10.7554/eLife.02935.019)10.7554/eLife.02935.020Figure 5---figure supplement 3.Negligible impacts of external mutagens (UV and tobacco smoking) to the somatic mtDNA mutations.No evidence of UV and tobacco smoking was identified even in melanoma and lung cancers, respectively. (Left) We compared the proportion of C \> T (and G \> A) substitutions in the CpC (GpG) context (mutational signature for UV \[[@bib1]\]) between melanomas and breast cancers (controls). Because UV shows trivial impact to the nuclear DNA somatic mutations of breast cancers ([@bib1]), the vast majority of mtDNA C \> T substitutions in the CpC context from breast cancers were not generated by UV. (Right) We compared the proportion of C \> A (G \> T) substitutions between lung and breast (control) cancers. C \> A (G \> T) substitutions are dominantly generated by tobacco smoking. Like UV, the impact of tobacco smoking to the somatic mutations of breast cancers is trivial ([@bib1]).**DOI:** [http://dx.doi.org/10.7554/eLife.02935.020](10.7554/eLife.02935.020)

We found 171 mtDNA substitutions in mitochondrial tRNA sequences, which are very similar to the expected number (168.2, p = 0.82) from the mutational signature. Interestingly, none of the substitutions was located in the trinucleotide anticodon site of the tRNA (expected number = 7.6, p = 0.006). This suggests that mutations in tRNA anticodons confer a similar selective disadvantage as protein-truncating mutations, presumably because such mutations would lead to systematic erroneous aminoacylation of nascent proteins during translation of the relevant codon.

Next, we assessed whether any specific somatic mutations showed evidence of positive selection. Out of the 1907 somatic substitutions, 16 (0.8%) overlapped with known disease-associated mtDNA mutations, such as mutations frequently detected in MELAS (Mitochondrial Encephalomyopathy, lactic acidosis, and stroke-like episodes) and LHON (Leber hereditary optic neuropathy) ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). In addition, ten mutations within mitochondrial protein-coding, tRNA and rRNA genes showed significantly higher recurrent rate than expected from background mutational signature ([Supplementary file 5](#SD5-data){ref-type="supplementary-material"}). However, it remains unclear whether this high recurrence reflects positive selection, because any factors not included in our background model of the mutational process, such as local mutation hotspots, could also explain a mild excess of mutations at a given nucleotide.

mtDNA mutations across tumor Evolution {#s2-7}
--------------------------------------

We investigated whether somatic mtDNA mutations are more likely to become homoplasmic later in tumor evolution by assessing paired cancer samples, either primary and metastasis (breast, colorectal, and prostate) or primary and relapse (myeloma) ([Figure 5B](#fig5){ref-type="fig"} and [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). As mentioned earlier, 73 late (metastasis or relapse) cancer samples were sequenced in addition to the primary tissues. Among the mtDNA mutations identified in either of the paired cancer samples, a number of different patterns were observed. There were mutations at high VAF in the primary not found in the metastasis (n = 49); mutations in the metastasis not found in the primary (n = 49); and shared mutations (n = 71) at high or low VAF, sometimes with evidence for drift (VAF difference \>0.2) between the two samples (n = 25). These data, particularly the mutations found in the metastasis only, suggest that mitochondrial mutations can occur throughout the time course of tumor evolution, and still drift to homoplasmy with appreciable frequency, as suggested previously ([@bib9]). To assess the plausibility of this conclusion, we modeled the dynamics of mtDNA mutations based on a few simplifying assumptions (See 'Materials and Methods', Evolutionary dynamics of neutral mitochondrial mutations). We find that the expected number of neutral mitochondrial mutations drifting to homoplasmy increases linearly with mutation rate and number of cell divisions. Based on a mutation rate of 10^−7^/base-pair/generation ([@bib9]; [@bib26]), this leads to an average ∼1 homoplasmic mutation for every 1000 cell generations.

Origins of mtDNA somatic mutations {#s2-8}
----------------------------------

We also explored whether the mutational forces that are so critical to shaping the nuclear genome during tumor evolution could affect the mitochondrial genome. In cancers associated with exogenous mutagens, such as tobacco-associated lung cancer and ultraviolet light-associated melanomas, we found no evidence of the mutational signatures characteristic of these carcinogens among the mtDNA mutations ([Figure 5C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). Moreover, *BRCA1* and *BRCA2* mutations showed no evident influence on mitochondrial genomes in breast cancer ([Figure 5C](#fig5){ref-type="fig"}), in contrast to their effects on nuclear genomes exhibiting an even distribution of mutations across all trinucleotide contexts ([@bib37]; [@bib1]). Taken together, it appears that the primary mtDNA mutational process is endogenous to mitochondria and is very different to those operating in nuclear DNA. It is surprising that the endogenous mutational process has far greater impact than any external forces, as the physicochemical interactions of ultraviolet light or the chemicals in cigarette smoke with DNA should be similar in both genomes. The simulations described above suggest the major explanation to be that the endogenous mutation rate is several orders of magnitude greater than that expected for exogenous carcinogens, thus swamping any signal.

Discussion {#s3}
==========

In theory, there are two potential sources of the mtDNA variants we observed in cancer tissues: (1) somatically acquired, or de novo, mutations accumulated during the cancer clone\'s lineage of cell divisions from the fertilized egg or (2) low-level heteroplasmic mtDNA present in the oocyte (therefore maternally inherited) amplified in cancer but lost from normal tissue by random drift ([@bib24]; [@bib17]; [@bib42]). We believe the majority of the variants we find are genuinely acquired somatically. First, of the 45 pairs of somatic mutations phased together on the same copy of the mtDNA genome, at least 33 (73.3%) showed a clear sub-clonal relationship and therefore their occurrence is separated in time, or apparently somatic. Secondly, 63.4% of our substitutions were not previously reported as germline polymorphisms. This is a much higher rate than reported for equivalent analyses on heteroplasmic variants in non-cancer samples (8/37; 21.6%) ([@bib35]), although methodological differences may somewhat contribute to this apparent difference ([@bib19]; [@bib3]). Thirdly, if the variants were due to inherited low-level heteroplasmy, we would not expect to see such variation across tissue types, since all tissue types derive from the fertilized egg. It is difficult to distinguish whether the variants we observe occur before or after the initiating driver mutations that herald tumorigenesis, but our analysis of paired samples does suggest that they can occur both early and late. Given the homogeneity of the mutational signature across tumor types and its inferred resemblance to the germline mtDNA mutational process, we would hypothesize that new mutations occur at a fairly constant and high rate per mitochondrial genome replication throughout all cell divisions.

On the basis of the mutational signature observed here, somatic substitutions are unlikely to be attributable to reactive oxygen species (ROS), as previous reports have suggested ([@bib45]; [@bib31]). Guanine oxidation by ROS predominantly causes G:C \> T:A transversion ([@bib53]; [@bib11]), which constitute only 4.0% of the mutations in our data ([Figure 5C](#fig5){ref-type="fig"}). Instead, we propose three replication-coupled mechanisms that can explain the strand asymmetric C~H~ \> T~H~ and T~L~ \> C~L~ mutational signature and define a model of the mtDNA mutational process ([Figure 5D](#fig5){ref-type="fig"}). First, the parent H strand, displaced and single-stranded during mtDNA replication ([@bib25]), could be more prone to cytosine deamination (generating C~H~ \> T~H~) and/or adenine deamination ([@bib36]; [@bib48]; [@bib13]) (generating T~L~ \> C~L~). Secondly, endogenous mtDNA polymerase (*POLG*) replication errors ([@bib59]) (which show the pattern of C \> T and A \> G substitutions) could be preferentially generated on the leading strand ([@bib41]). Thirdly, there may be differences between the efficiency of repair between the leading and lagging strand ([@bib40]). Further, the mutation pattern reported here is consistent with the hypothesized bidirectional initiation of mtDNA genome replication ([@bib58], [@bib57]; [@bib25]).

It appears that most of the mtDNA missense mutations we observe become fixed in tumor progenitor cells without distinct physiological advantage. All the statistical testing performed in this study---variant allele fraction comparison across different categories of somatic mutations, number of recurrent mutations, and dN/dS ratio---suggest that mtDNA somatic substitutions accumulate largely neutrally. This is not different from previous observations in nuclear genomes: of the thousands of somatic mutations found in a cancer genome, many fewer than a hundred are believed to confer a selective advantage to the cancer cell ([@bib51]). In contrast, protein-truncating mutations showed evidence of negative selection, at the level of constraints on the allele fraction achieved. The implication of this is that the inactivating mutations occur at an appreciable rate, but the fraction of mitochondrial genomes per cell carrying these variants cannot increase beyond a certain limit without impairing the selective fitness of that cell. Having a sizable number of mitochondria with fully intact proteome remains critical to the fitness of a cancer cell.

Materials and methods {#s4}
=====================

Sequencing data {#s4-1}
---------------

All the sequences were generated by Illumina platforms (either Genome Analyzer or HiSeq 2000). With respect to TCGA data, we downloaded aligned bam files through UCSC CGHub (<http://cghub.ucsc.edu>). Sequencing reads were aligned on the human reference genome build 37 (GRCh37) and human reference mtDNA sequence (revised Cambridge reference sequence, rCRS \[[@bib2]\]), mainly by BWA alignment tool. Samtools ([@bib34]) and Varscan2 ([@bib29]) were used for manipulating sequence reads and for calling somatic mutations, respectively. Sequence data have been deposited in the European Genome-phenome Archive (EGA; <https://www.ebi.ac.uk/ega/home> ; study accession \# EGAS00001000968; dataset accession numbers EGAD00001001014 for primary samples and EGAD00001001015 for metastatic samples). Sample accession numbers are available in the [Supplementary file 6](#SD6-data){ref-type="supplementary-material"}.

Off-target mtDNA reads in whole-exome sequencing {#s4-2}
------------------------------------------------

Most of the currently available whole-exome capture kits, including Agilent Technologies SureSelect Human All Exon 50 Mb (Agilent Technologies Inc., Santa Clara, CA) used mostly in this study, do not target mtDNA genes ([@bib14]). However, because of the abundance of mtDNA in human cells (100--100,000 copies per cell), it is expected that a number of mtDNA fragments could be off-target captured. We checked whether the amount of off-target mtDNA reads was sufficient for mtDNA variant detection. Whole-exome sequencing (normal samples) generated by CGP (n = 855), WUGSC (Washington University Genome Sequencing Center; n = 140), and BCM (Baylor College of Medicine; n = 85) contained ∼100 off-target mtDNA reads per 1M autosomal reads ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). We concluded that these could be sufficient for the downstream analyses, because ordinary 10 Gb whole-exome data would provide ∼60× read depth for mtDNA here. However, whole-exome data sequenced by BI (Broad Institute; n = 436) included far less, ∼3 off-target mtDNA per 1 M autosomal reads, which would show ∼2× mtDNA read depth per 10 Gb exome sequencing ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). It may be due to 'improved' exome-capture protocols by BI to increase the DNA-capture efficiency and on-target rate ([@bib16]). Therefore, we did not include whole-exome data sequenced from BI for further analysis.

139 samples were sequenced by both whole-genome and whole-exome sequencing. From these, we compared the amount of off-target mtDNA reads from whole-exome sequencing with that of whole-genome sequencing. It showed clear positive linear correlation ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

DNA cross-contamination {#s4-3}
-----------------------

Given the abundance of mtDNA in the cancer cells, 1--214× coverage cancer whole nuclear genome sequencing provides extensive coverage of mtDNA (average read depth = 7901.0×; [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}) enabling accurate identification of somatic mutations, even if heteroplasmic. Whole-exome sequencing data were also included because off-target reads provided sufficient coverage (average read depth = 92.1×) to analyze mtDNA mutations.

This high coverage of mtDNA, especially from whole-genome sequencing, permitted us to identify heteroplasmic variants (our detection threshold was 3%; see 'Variant calling' for more details). However, because sample swaps and/or DNA cross-contaminations would definitely generate false-positive somatic variants, we filtered out suspicious DNA samples as described below.1. Major sample swapsA subset of tumor and normal sequencing pairs, of which the nuclear genotypes were not matching with each other, were removed from further analyses. We randomly selected 320 common single-nucleotide polymorphism sites on the 22 human autosomes, of which the minor allele frequency is ∼50% (45--55%) according to The 1000 Genomes Project ([@bib18]). Of the 320 sites, homozygous positions in normal tissues (which showed \>90% variant allele fraction (VAF) with bases Q score \>20) were compared with the corresponding genotypes in the counterpart cancer. Sample pairs were removed if the genotype mismatch rate was greater than 0.1 ($\frac{Nhet + Nwt}{Nhom + Nhet + Nwt}$; *N*~*het*~, number of heterozygote positions; *N*~*hom*~, number of homozygote positions; *N*~*wt*~, number of wild-type positions) ([Figure 1---figure supplement 5A](#fig1s5){ref-type="fig"}). We note 0 is expected for the rate when genotyping is perfect and sample pairs are from the same individual. By contrast, 0.5 is expected when samples were from different individuals.2. Minor cross-contaminationWe estimated DNA cross-contamination levels with the VAF of autosomal homozygous SNPs genotyped from the common (population minor allele frequency ∼50%) SNP sites. Theoretically, if there is no sequencing (and mapping) error, all the homozygote SNP sites in pure samples should present 100% VAFs. However, when samples are contaminated, corresponding VAFs are reduced because the contaminant has only an ∼25% of chance of having homozygote SNPs on the same site. Therefore, minor contamination levels (C) of each cancer sequencing data were estimated as below:$$C = 2 \times \frac{\sum\left( RCwt \right) - Ne}{\sum\left( RDhom \right) - Ne},$$where *RD*~*hom*~ is sequencing read depth, *RC*~*wt*~ is read-count of wild-type alleles, and *Ne* is number of sequencing errors on each autosomal homozygote SNP site. For high accuracy, we only counted base with sufficient quality score (Q \> 20). In order to estimate *Ne*, we assumed a conservative rate (sequencing error rate = 0.001). We considered sites covered by at least 10 reads and 90% VAF ([Figure 1---figure supplement 5B](#fig1s5){ref-type="fig"}). 95% confidence intervals of cross-contamination levels were calculated using binomial distribution.In order to clear somatic variants, here we made the very conservative assumption that somatic variants present in excess of 5-times of the 95% upper limit of C levels were true somatic rather than false-positives by low-level of cross-contamination.3. Germline polymorphisms and back mutationsWe further checked samples for contamination using known mtDNA polymorphisms. Because human mtDNA is small (16,569 bp) and extensively explored previously, most of germline mtDNA polymorphisms are already known. For example, 97.7% of the 39,036 inherited substitutions were known polymorphisms in the mtDB database ([@bib27]). Therefore, when a tumor sample is contaminated by other samples, many somatic-like mtDNA substitutions by contaminants are likely to be overlapped with known mtDNA polymorphisms.At the same time, low-level contamination would generate excessive back mutations, which appeared to reverse germline common polymorphisms into wild-type alleles. Taken together, both the number of somatic substitutions known in mtDB and number of back mutations can be good indicators for mtDNA cross-contamination. Therefore, we filtered out tumor tissues with ≥3 known potentially somatic mutations or with ≥2 back mutations from the further analyses ([Figure 1---figure supplement 5A and B](#fig1s5){ref-type="fig"}).

Variant calling {#s4-4}
---------------

We extracted mtDNA reads using Samtools ([@bib34]). We used VarScan2 ([@bib29]) for initial variant calling with a few options (\--strand-filter 1 (mismatches should be reported by both forward and reverse reads), \--min-var-freq 0.03 (minimum VAF 3%), \--min-avg-qual 20 (minimum base quality 20), \--min-coverage 3 and \--min-reads2 2). With respect to the \--strand-filter, it generally removes variant when \>90% of mismatches are reported from either of the H or the L mtDNA strand. However, where only reads with a specific orientation are could be aligned dominantly (i.e. in both extreme region of mitochondrial reference genome; only L strand reads could be aligned on the 5′ extreme of mtDNA), we compared strand bias between 'perfect matches' (\# perfect matches from L strand reads / total \# perfect matches) and mismatches (\# mismatches from L strand reads / total \# mismatches). If the difference between those two bias \<0.1, the mutations were rescued. Of the 1907 mutations, 54 (2.8%) were rescued accordingly.

Putative somatic variants called by VarScan2 were further filtered using criteria shown below.At least 4 unique reads supporting variants and all variant reads at least 20 phred scale sequencing quality score (Q 20 = 1% sequencing error rate) and at least 3% variant allele fractions (VAFs).A. Regardless of in WGS and in WES, the ≥4 mismatches and the ≥3% VAF criteria must be satisfied simultaneously.B. However, in WGS, the minimum number of reads (n = 4) criterion is not essential, because the ≥3% VAF criterion is much more stringent (3% VAF request at least 240 mismatches (\>\>4) given mtDNA coverage is ∼8000 for WGS).C. In WES, the ≥3% VAF criterion is relatively less important than in WGS, because the ≥4 mismatches criterion is more stringent. For example, 4 mismatches in 90x (WXS average) coverage region (VAF = 4.4%) automatically fulfill the ≥3% VAF criterion. For less covered regions (i.e. \<40x coverage; n = 285 out of total 1907 substitutions), the VAF criterion becomes less important, because 4 mismatches would generate ≥10% VAF, much higher than the minimum threshold (i.e. 3%). As results, we are missing lower heteroplasmic variants (i.e. variants with 3--10% heteroplasmic levels) from low coverage samples (mostly by WXS). The lower sensitivity of WXS is also confirmed in our validation study (see "Validation of somatic variants" below).There is no minimum threshold for total coverage (\# perfect matches + \# mismatches).To increase sensitivity for detecting mutations, we rescued mutations with 3 unique variant reads (with at least 20 phred scale sequencing quality score) when VAFs is ≥ 20%. Of 1907 somatic substitutions, 32 (1.7%) were rescued accordingly.All somatic variants presenting with VAFs lower than our very conservative threshold for minor cross-contamination (5-times 95% upper limit of contamination levels for each tumor sample, see above "Minor cross-contamination of DNA samples") were removed. When we could not estimate cross-contamination levels because of low sequencing depth of coverage (for nuclear genome), a conservative criterion (10% contamination level threshold) was explicitly used.Substitutions were further visually inspected using IGV ([@bib54]). Thirteen frequent false-positive variants (shown below) by misalignment due to extensive level of homopolymers in rCRS and due to sequencing error in the reference mtDNA genome (3107N, see Mitomap (<http://www.mitomap.org/bin/view.pl/MITOMAP/CambridgeReanalysis>) for more information) were explicitly removed:1. Misalignment due to ACCCCCCCTCCCCC (rCRS 302-315)A302C, C309T, C311T, C312T, C313T, G316C2. Misalignment due to GCACACACACACC (rCRS 513-525)C514A, A515G, A523C, C524G3. Misalignment due to 3107N in rCRS (ACNTT, rCRS 3105-3109)C3106A, T3109C, C3110A

We compared our variant calls with common inherited mtDNA polymorphisms deposited in the mtDB database as of 24th July 2013 ([@bib27]). Gene annotation of somatic variants was done using custom script based on human mtDNA gene information ([@bib47]).

Validation of somatic variants {#s4-5}
------------------------------

To validate the sensitivity and specificity of variant calling in this study, 19 tumor and normal pairs (which were originally whole-genome sequenced) were whole-exome sequenced and mtDNA variants were assessed independently. Among the 28 somatic substitutions originally detected from the 19 tumor--normal whole-genome sequencing pairs, 20 (71.4%) were called as somatic ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). In addition, 5 (17.9%) presented evidence of variant reads in the validation set, although it was filtered out because of its low read depth of coverage in exome sequencings (showed 2--5 variant reads). Moreover, because 3 remaining sites were not sufficiently covered in the validation set to call somatic variants, these could not be evidence of the inaccuracy of whole-genome sequencing data, therefore not considered in the accuracy validation. Taken together, all the 25 somatic substitutions by whole-genome sequencing were highly likely to be true positives, therefore we concluded it provided ∼100% accuracy in the mtDNA somatic substitution assessment. Actually, the high accuracy of whole-genome sequencing is very likely and what we expect, because it provides extensive coverage of mtDNA (average read depth \>7,500×), ∼3% heteroplasmic variants would present \>200 variant reads.

By contrast, the validation set (whole-exome sequencing) is called 21 somatic substitutions. Of these, 20 were common with whole-genome sequencing, and one was incorrectly called as somatic though it was actually germline substitutions in the whole-genome sequencing data. In addition, as mentioned above, the validation set missed 8 somatic substitutions called by whole-genome sequencing. Six out of eight undercalls (75%) were low heteroplasmic substitutions in whole-genome sequencing, ranging from 3.36% to 8.68%. Based on these data, we suggest 71.4% sensitivity (20/28) and 95.2% specificity (20/21) for exome-sequencing in detecting upto 3% heteroplasmic somatic mtDNA substitutions in cancer.

We further checked the correlation of heteroplasmy level between the 20 mtDNA somatic mutations called both whole-genome and whole-exome sequencing. It showed great linear relationship (R^2^ = 0.97, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), further suggesting whole-exome sequencing data are appropriate for accurate detection of mtDNA somatic mutations.

Substitution phasing {#s4-6}
--------------------

We phased 72 somatic substitution pairs, which arose in a single cancer sample and which located sufficiently close (from 10 bp to ∼500 bp), therefore both sites could be sequenced by same sequence fragments ([Supplementary file 3](#SD3-data){ref-type="supplementary-material"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). We classified them as 'different strand', 'co-clonal', and 'sub-clonal' using criteria as follows:

Different strand: the two somatic substitutions are obligate on different strands. Reads that report wild-type1(wt)-substitution2(subs) and subs1-wt2, but subs1-subs2, are observed.

Co-clonal: reads reporting wt1-wt2 and subs1-subs2 are only observed.

Sub-clonal: One substitution is sub-clonal to the other, but the two are definitely phased. Reads subs1-subs2 and either subs1-wt2 or wt1-subs2 are observed.

Tumor type and mtDNA somatic substitutions {#s4-7}
------------------------------------------

To understand the relationship between tumor types and number of mtDNA mutations, Poisson regression and ANOVA were applied to our dataset using R software (<http://www.r-project.org>).$$\text{Fit}1 < - \text{glm}\left( \text{N}_{\text{sub}}\text{∼}\text{Cov}_{\text{T}} + \text{Cov}_{\text{N}}\text{, family} = \text{poisson}{()} \right)$$$$\text{Fit}2 < - \text{glm}\left( \text{N}_{\text{sub}}\text{∼}\text{Cov}_{\text{T}} + \text{Cov}_{\text{N}} + \text{t, family} = \text{poisson}{()} \right)$$$$\text{anova}\left( \text{Fit}1\text{, Fit}2\text{, test} = \text{“Chisq”} \right)\text{,}$$where N~sub~ is number of mtDNA substitutions of each sample, Cov~T~ and Cov~N~ are coverage of tumor and normal mtDNA, respectively, (if Cov is \>200, we replaced it by 200), t is tumor types.

Age and mtDNA somatic substitutions {#s4-8}
-----------------------------------

Poisson regression was applied to our breast cancer dataset.$$\text{Fit}1 < - \text{glm}\left( \text{N}_{\text{sub}}\text{∼}\text{Cov}_{\text{T}} + \text{Cov}_{\text{N}} + \text{a, family} = \text{poisson}{()} \right)$$where N~sub~ is number of mtDNA substitutions of each sample, Cov~T~ and Cov~N~ are coverage of tumor and normal mtDNA, respectively, (if Cov is \>200, we replaced it by 200), a is age at diagnosis. p-value in estimation of a was shown in the manuscript.

Mutational signature and strand bias {#s4-9}
------------------------------------

Different mutational processes generate different combinations of mutation types, termed 'signatures' ([@bib37]). For example, ultraviolet (UV) light and tobacco smoking (polycyclic aromatic hydrocarbons) frequently generate C \> T transitions and G \> T transversions on non-transcribed (coding) strands in melanoma and lung cancers, respectively ([@bib43], [@bib44]). To understand the mutational processes influencing cancer mtDNA, we correlated the 1907 mtDNA substitutions with 21 cancer specific mutational signatures in the nuclear DNA recently identified ([@bib1]). However, none of the signature could explain the highly unique mtDNA substitutions.

Mutational signature and strand bias were assessed as described in our previous reports ([@bib1]). Briefly, the immediate 5′ and 3′ sequence context was extracted from rCRS. Substitution rate for each trinucleotide context was calculated with the number of substitution normalized by the frequency of the trinucleotide context observed in the rCRS, in the L and H strand, respectively. For analyses of substitutions falling in the mtDNA genes (13 protein-coding and 22 tRNA genes), transcribed/non-transcribed strand was also considered for comparison.

In order to prove the strand bias is not transcription but replication-coupled, we checked strand biases of polymorphisms in the 12 L strand protein-coding genes, 1 H strand protein-coding gene (*MT-ND6*), and/or 22 tRNAs ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). For this specific purpose, we did not consider the sequence context (immediate 5′ and 3′ bases) because it over-classifies mutations (i.e. the number of mutation classes (n = 96) is larger than that of mutations). In other words, 12 classes of substitutions (six classes of possible base substitutions (C \> A, C \> G, C \> T, T \> A, T \> C, T \> G) × two strands (L and H strands)) were considered. Substitution rates are ratio between observed and expected numbers (H~0~ = same mutation rate for all substitution classes) for each substitution class. In order to understand which model (replicative or transcriptional strand) is appropriate to explain the strand-bias, Chi-square tests were used between the number of observed mutations for each class and expected ones under the background signature.

mtDNA codon usage {#s4-10}
-----------------

We counted the codon frequencies in 13 mtDNA protein-coding genes. Because 12 L strand protein-coding genes and 1 H strand gene (*MT-ND6*) are under opposite mutational pressure (T \> C and G \> A for L strand genes; A \> G and C \> T for *MT-ND6*), we separated L and H strand genes for this analysis. T \> C skew and G \> A skew were calculated as shown below, to understand the T~L~ \> C~L~ and C~H~ \> T~H~ (equivalent to G~L~ \> A~L~) substitutions during the evolution of human mtDNA:$$\text{T} > \text{C}_{\text{skew}} = \frac{N_{\text{C}} - N_{\text{T}}}{N_{\text{C}} + N_{\text{T}}}\quad and\quad\text{G} > \text{A}_{\text{skew}} = \frac{N_{\text{A}} - N_{\text{G}}}{N_{\text{A}} + N_{\text{G}}}\text{,}$$where *N*~A~, *N*~C~, *N*~G~, and *N*~T~ are number of A, C, G, and T base in the 3^rd^ position of triplet codons in mtDNA genes, respectively.

For the assessment of mtDNA codon usage of other animal species, we analyzed the mtDNA sequence of *Caenorhabditis elegans* (accession\# NC_001328), *Drosophila melanogaster* (accession\# NC_001709), *D. rerio* (accession\# NC_002333), *Xenopus laevis* (accession\# NC_001573), *Mus musculus* (accession\# EU450583), *Gallus domesticus* (accession \# NC_235570), and *Pan troglodytes* (NC_001643). We considered only L strand mtDNA genes in the cross-species analysis.

Recurrent substitutions {#s4-11}
-----------------------

To compare the number of recurrent substitutions between silent and missense substitutions, we randomly selected 100 substitutions each from 198 silent substitutions in the third base of triplet codons, 440 missense substitutions in the first base of triplet codons, and 405 missense substitutions in the second base of triplet codons. We counted the number of recurrent substitutions in each group. This was iterated 300 times independently. ANOVA testing was applied to determine the difference between the three groups ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

dN/dS ratio {#s4-12}
-----------

To estimate dN/dS values for missense mutations (w~mis~), we used an adaptation of the method described previously ([@bib22]). Briefly, the rate of mutations is modeled as a Poisson process, with a rate given by a product of the mutation rate and the impact of selection. To obtain accurate estimates of dN/dS, we used two separate models, one using 12 single-nucleotide substitution rates and a more complex one accounting for any context dependence effect by 1-nucleotide upstream and downstream using 192 substitution rates. For example in the 12-rate model, the expected number of A \> C mutations (**λ**~A\>C~) would be modeled as follows:$$\lambda_{\text{syn},\text{A} > \text{C}} = \text{r}_{\text{A} > \text{C}}\text{*}\text{L}_{\text{syn},\text{A} > \text{C}}$$$$\lambda_{\text{mis},\text{A} > \text{C}} = \text{r}_{\text{A} > \text{C}}\text{*}\text{w}_{\text{mis}}\text{*}\text{L}_{\text{mis},\text{A} > \text{C}}$$where L~syn,A\>C~ and L~mis,A\>C~ are the number of sites that can suffer a synonymous and missense A \> C mutation, respectively, which are calculated for any particular sequence. The likelihood of observing the number of missense A \> C mutations (N~mis,A\>C~) given the expected **λ**~mis,A\>C~ is then calculated as:$$\text{Lik} = \text{Poisson}\left( \text{N}_{\text{mis},\text{A} > \text{C}}\text{ | }\text{r}_{\text{A} > \text{C}},\text{w}_{\text{mis}} \right)$$and the likelihood of the entire model is the product of all individual likelihoods. W~mis~ is fixed to be equal in all 12 (or 192) equations describing each substitution type, and a hill-climbing algorithm is used to find the maximum likelihood estimates for all rate and selection parameters. Likelihood Ratio Tests are then used to test deviations from neutrality (w~mis~ = 1). The dN/dS ratio reported in the main text corresponds to the full context dependent model with 192 substitution rates. This method allows quantifying the strength of selection avoiding the confounding effect of gene length, sequence composition, different rates of each substitution type, and context-dependent mutagenesis.

Short indels {#s4-13}
------------

Along with the 1907 somatic mtDNA substitutions, we identified 109 and 142 somatic short insertions and deletions, respectively, from the 1675 cancer mtDNA sequences using Varscan2 ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}).

Evolutionary dynamics of neutral mitochondrial mutations {#s4-14}
--------------------------------------------------------

We model the evolutionary dynamics of mitochondrial mutations under random drift and derive a simple equation for the expected number of homoplasmic mutations. There exist multiple levels at which mitochondrial mutations evolve: within mitochondria, in the cytoplasm, and on the cellular level ([@bib46]). In this study, we focus on the dynamics in a single cell, which represents the founder of the last clonal expansion in the tumor cell population. The cellular dynamics during a clonal expansion is difficult to describe analytically, but it is important to realize that mutations of a clonal expansion preserves the allele frequencies of neutral variants and that mutations that occur after the expansion are unlikely to contribute to measurable allele frequencies, as the population becomes large.

We model the evolutionary dynamics of mitochondrial mutations in the cytoplasm of a single cell by a Wright--Fisher process ([@bib56]), in which the number of mitochondria in a subsequent generation is a binomial sample of the mitochondria in the previous generation. The number of mitochondria *M* is kept fixed. The marginal allele frequency *X* of a single site has two absorbing boundaries, *X* = 0 and *X* = *M* (homoplasmy), and the probability of fixation of an allele at frequency *X* by neutral drift is *ρ* = *X*/*M* ([@bib56]). Note that this process leads, on the population level, to a dichotomization of heteroplasmic variants to either go extinct or become homoplasmic and fixate in a cell.

Mutations on any of *L* (= 16,569 nt) sites in the mitochondrial genome are assumed to occur at a uniform rate *μ* per nucleotide per cell division, which is of order 10^−7^, based on a human inter-generational comparison ([@bib9]). Hence the rate of neutral evolution is simply *μLM*/*M* = *μL* ([@bib28]). Lastly, the expected time to fixation in the Wright--Fisher process is *t* = *2M*. Putting these things together, the expected number of mutant alleles *N* in a cell initially without any mitochondrial mutations after *T* generation is$$\text{E}\left\lbrack N \right\rbrack = \text{μ L}\left( T - 2M \right)$$

This equation predicts a linear accumulation of neutral mutations over time, with a delay imposed by number of mitochondrial copies. A similar behavior has been reported using numerical simulations ([@bib9]). When also considering heteroplasmic mutations, the expected number of alterations may be slightly higher.

To check whether our model yields the correct behavior, we use the following numbers: the observed order of magnitude of mitochondrial mutations per patient was N = 1. The sequencing coverage on the mitochondrial genome indicates that there were of order M = 100 mitochondrial genome copies present per cancer cell. The expected number of mutations per cell division is *μL* = 1.6 × 10^−3^, it therefore requires around 1000 cell generations *T* to accumulate on average one homoplasmic mutation. This number of generations appears realistic for regenerating tissues. As expected, epithelial cancers had among the highest observed number of mitochondrial mutations, while hematopoietic cancers typically had lower numbers.

Statistical testing {#s4-15}
-------------------

Statistical testing was performed using R software. All p-values were calculated by two-tailed testing. Figures were generated using R and Microsoft Excel software.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "Origins and functional consequences of somatic mitochondrial DNA mutations" for consideration at *eLife.* Your article has been favorably evaluated by Stylianos Antonarakis (Senior editor), a Reviewing editor, and 3 reviewers.

The editors and the reviewers discussed their comments before we reached this decision, and the Senior editor has assembled the following comments to help you prepare a revised submission.

The substantial concerns of the 3 reviewers are:

*Reviewer 1*:

1\) Is the generated sequence data accessible through a public repository such as GEO? Are database accession numbers provided somewhere in the manuscript.

2\) [Figure 3--figure supplement 1](#fig3s1){ref-type="fig"} is an example of possible artifacts in the authors\' results/interpretation. This figure compares the substitution rates between 12 coding genes on heavy strand vs 1 on light strand, but information on how the graph was generated for the 12 genes cannot be found. Does the graph show the sum or average of observed substitution rates? If it is based on average rates, should there not be error bars or p-values from t-tests. Also, why are the 12 genes shown for the L strand, and the 1 gene as the H strand?

3\) In [Figure 4](#fig4){ref-type="fig"}, what are the authors trying to demonstrate with [Figure 4A](#fig4){ref-type="fig"}? What do arrows beside the "box" indicate? What do the different colors of the arrow (blue and red) mean? Why is the "box" designed for the light strand sequence when it has only 1 out of 13 protein-coding genes? What does skew mean here?

*Reviewer 2*:

1\) Do the authors observe differences between tumor types in terms of the relative proportion of negatively selected somatic mutations that are hetero- vs. homoplasmic? This may indicate differential (negative) selective pressures in different tumor types (e.g. negative selection could be less pronounced in tumors with a low rate of oxidative phosphorylation).

2\) The authors suggest that the major explanation for lack of visible exogenous mutation signatures (i.e. such related to tobacco smoke or UV light exposure) is that the endogenous mutation rate in mitochondria is several orders of magnitude greater than the exogenous mutation rate. Can the authors, based on the rate of nuclear genome somatic mutations in tumors with pronounced exogenous mutation signatures (i.e. using data from earlier works by the authors) provide an estimate for the relative difference in endogeneous vs. exogeneous mutation rate?

*Reviewer 3*:

1\) Several studies have already used massive parallel sequencing data for the identification of heteroplasmic mutations in cancer (He et al Nature 2010) and in normal samples ([@bib19]; [@bib3]; [@bib42]). These studies already set the standards for such analyses, which to a large extent were overlooked in the current manuscript. As an example, the authors used a threshold of \>3% of the reads to be considered as trustworthy heteroplasmic mutations but the minimum coverage that they used does not allow such a threshold (10X!). Other studies used at least 100X (a minimum) or even 1000X coverage (preferable) and a threshold of 1.5% of the reads. Apart from the threshold issue, while considering secondary reads in the mtDNA (heteroplasmy) one should apply several filters such as \'no strand bias\', unique mapping (NuMT exclusion) and \'exclusion of mutations at the end of reads\'. These should be used in the revised manuscript and the list of mutations should be updated accordingly. These filters are especially important, since the authors give much weight for their strand bias hypothesis and replication-associated mutations. However, nothing is mentioned as to how the authors account for strand bias (i.e. mutations present mostly in forward or reverse reads). Until they exclude sequencing artifacts, including those resulting from strand bias, they cannot interpret the data as actual biological strand bias.

2\) The authors claim that their analysis was unbiased and generated a catalogue of somatic mtDNA mutations. However, they excluded all candidate somatic mutations that recapitulated known mtDNA SNPs. The exclusion of SNPs is understood while considering the nuclear genome, however unlike the nuclear DNA the mtDNA molecule is in full linkage disequilibrium. This means that in order to avoid sample contamination the authors should exclude mutations in SNP positions ONLY when they phase along with other SNP mutations to form a haplotype.

3\) The functional potential of mutations is not properly analyzed: dN/dS ratio calculated for genes does not reflect the functionality of specific mutations. Some estimation could be given by manipulations of this ratio using PAML or SELECTON. However the best way to assess the functional potential of variants is a comparison to disease causing mutations.

10.7554/eLife.02935.028

Author response

Reviewer 1:

*1) Is the generated sequence data accessible through a public repository such as GEO? Are database accession numbers provided somewhere in the manuscript*.

We have submitted our sequencing data to EBI. Corresponding accession numbers are available at [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. It may be finally updated after acceptance.

*2)* [*Figure 3--figure supplement 1*](#fig3s1){ref-type="fig"} *is an example of possible artifacts in the authors\' results/interpretation. This figure compares the substitution rates between 12 coding genes on heavy strand vs 1 on light strand, but information on how the graph was generated for the 12 genes cannot be found. Does the graph show the sum or average of observed substitution rates? If it is based on average rates, should there not be error bars or p-values from t-tests. Also, why are the 12 genes shown for the L strand, and the 1 gene as the H strand*?

We have updated our manuscript. In Materials and methods, section "Mutational signature and strand bias", we describe how we calculated the substitution rates in more detail. In addition, we addressed chi-square tests to quantify the extent of difference in mutational signatures (Figure legends for [Figure 3--figure supplement 1](#fig3s1){ref-type="fig"}). Of the 13 protein-coding genes in mtDNA, we obtained their strands from human reference mtDNA sequence (rCRS). Notably, only 1 gene (MT-ND6) has its coding sequence on the H strand.

*3) In* [*Figure 4*](#fig4){ref-type="fig"}*, what are the authors trying to demonstrate with* [*Figure 4A*](#fig4){ref-type="fig"}*? What do arrows beside the "box" indicate? What do the different colors of the arrow (blue and red) mean? Why is the "box" designed for the light strand sequence when it has only 1 out of 13 protein-coding genes? What does skew mean here*?

This figure explains how the somatic mutational signature is identical or very similar to the germline one, observed across evolutionary time. From this, we conclude the mutational processes that shaped human mitochondria over time generate de novo mtDNA mutations in somatic tissues. Thus, the germline signature of human mtDNA can be inferred from codon usage biases (T\>C skew and G\>A skew; Materials and methods, "mtDNA codon usage"), which present T\>C and G\>A (L strand manner) exactly as observed in somatic substitutions. The arrows beside the box highlight the T\>C (red) and G\>A (blue) substitutional pressures in germline mtDNA. We have updated these in the figure legends of [Figure 4A](#fig4){ref-type="fig"}. The numbers in the box are based on 12 "L strand genes (genetic codes on the L strand, or transcribed from the H strand)", not from 1 "H strand gene".

Reviewer 2:

*1) Do the authors observe differences between tumor types in terms of the relative proportion of negatively selected somatic mutations that are hetero- vs. homoplasmic? This may indicate differential (negative) selective pressures in different tumor types (e.g. negative selection could be less pronounced in tumors with a low rate of oxidative phosphorylation)*.

This is an interesting suggestion. Using 166 protein-truncating mutations, we tested the difference in variant allele fractions across tumor types. We have shown our results in the [Figure 5--figure supplement 2](#fig5s2){ref-type="fig"} and have updated our manuscript accordingly. Interestingly, colorectal cancers show less extent of such constraints on mtDNA protein-truncating mutations.

Amended to: The extent of such disadvantage may vary according to tumor type: for example colorectal cancers show less negative selection compared to breast cancers (p=0.028; [Figure 5--figure supplement 2](#fig5s2){ref-type="fig"}).

*2) The authors suggest that the major explanation for lack of visible exogenous mutation signatures (i.e. such related to tobacco smoke or UV light exposure) is that the endogenous mutation rate in mitochondria is several orders of magnitude greater than the exogenous mutation rate. Can the authors, based on the rate of nuclear genome somatic mutations in tumors with pronounced exogenous mutation signatures (i.e. using data from earlier works by the authors) provide an estimate for the relative difference in endogeneous vs. exogeneous mutation rate*?

We tried to estimate the impact of ultraviolet light (UV) and tobacco smoking in the somatic mtDNA mutations as the reviewer suggested. We did not find any evidence that there were any mutations that could be unambiguously attributed to these mutational processes. We have added [Figure 5--figure supplement 3](#fig5s3){ref-type="fig"} to summarize our estimates. Thus, it is impossible to estimate the relative difference between endogenous and exogenous mutation rates. Potentially, with larger sample sizes of these tumour types, this will be feasible.

According to the mutational signatures in the nuclear genomes reported by [@bib1], UV and tobacco smoking are the most important exogenous mutagens. The mutational signatures of UV and tobacco smoking are C\>T substitution at a dipyrimidine context and C\>A substitution, respectively.

1\) UV:

From 26 samples of melanoma, of which the UV mutational signature is found in each sample and accounts for \>90% of somatic mutation in each nuclear genomes, we found 15 C\>T (or G\>A) mtDNA mutations. Of these, 12 (80%) were at dipyrimidine contexts. As controls, breast cancers mostly free from UV, we found 289 C\>T (or G\>A) substitution, and 227 (78.5%) were from dipyrimidine context. Because the proportions of C\>T at dipyrimidine context are the same (chi-square test p=0.54) between melanomas and breast cancers, it is highly unlikely that the UV signature generates the mtDNA mutations even in the melanoma samples.

2\) Tobacco smoking:

Tobacco signature is dominant in lung cancer nuclear genomes (61% for lung adenocarcinoma; 93% for small cell lung cancer; 45% for squamous cell carcinoma). In contrast, the mutational signature of tobacco smoking has not been previously found in breast cancer nuclear genomes (Alexandrov et al., Nature 2013). Of the 83 mtDNA somatic mutations in lung cancers, 3.6% (n=3) are C\>A (or G\>T) substitutions. From breast cancers, 4.7% of somatic mtDNA substitutions are C\>A (or G\>T) mutations. Because we cannot identify any C\>A substitution enrichment in lung cancers, the impact of tobacco smoking is also minimal, approximately 0%.

Reviewer 3:

*1) Several studies have already used massive parallel sequencing data for the identification of heteroplasmic mutations in cancer (He et al Nature 2010) and in normal samples (*[@bib19]*;* [@bib3]*;* [@bib42]*). These studies already set the standards for such analyses, which to a large extent were overlooked in the current manuscript. As an example, the authors used a threshold of \>3% of the reads to be considered as trustworthy heteroplasmic mutations but the minimum coverage that they used does not allow such a threshold (10X!). Other studies used at least 100X (a minimum) or even 1000X coverage (preferable) and a threshold of 1.5% of the reads*.

The threshold ("10x") mentioned by the reviewer is not for "mtDNA somatic mutations" but for "autosomal SNPs" to assess "minor cross-contamination levels" (see Materials and methods, "DNA cross-contamination" section). As we described in the manuscript, average read-depths for mitochondrial DNA from WGS and WXS are 7,901x and 92x. For 1,907 somatic polymorphisms, the average and median read-depths are 4,560x and 419x, respectively. Our findings are based on "high-coverage mtDNA sequencing" like the previous studies the reviewer mentioned. It is worthy of note that WES is not as sensitive as WGS for mtDNA somatic mutations, but is sufficiently sensitive (71.4%) to provide useful information. With respect to the threshold (\>3%), we decided to be more conservative compared to previous studies (1.5%), because copy number amplifications are very frequent in cancer cells, thus the influence of NuMTs in this study could be higher than previous studies from normal samples. Finally, we would like to emphasize that the major conclusions of the manuscript (the mutational signature and strand bias in mtDNA, and the lack of positive selection on mutations) are independent of the thresholds used.

*Apart from the threshold issue, while considering secondary reads in the mtDNA (heteroplasmy) one should apply several filters such as \'no strand bias\', unique mapping (NuMT exclusion) and \'exclusion of mutations at the end of reads\'. These should be used in the revised manuscript and the list of mutations should be updated accordingly. These filters are especially important, since the authors give much weight for their strand bias hypothesis and replication-associated mutations. However, nothing is mentioned as to how the authors account for strand bias (i.e. mutations present mostly in forward or reverse reads). Until they exclude sequencing artifacts, including those resulting from strand bias, they cannot interpret the data as actual biological strand bias*.

Most of the filters suggested by the reviewer were already applied in the original manuscript. Most importantly, we used the "strand-filter" (see Materials and methods, "Variant calling" section (strand-filter 1) and Supplementary Table 2). Therefore, we are very confident that the strand bias which is observed in the somatic substitutions is not an artifact from detection, or "mutations present mostly in forward OR reverse reads". Additionally, we used only uniquely mapped reads in the mutation calling algorithm. We also note that the alignment algorithm simultaneously maps against the nuclear and mitochondrial genomes, so that reads from the NuMT regions will map to the nucleus, and not be included in the analysis presented here. We did not apply a "read-end filter". To evaluate whether this would have had an impact, we checked 130 randomly selected mtDNA mutations. Only 2 were called as mutations based on mismatches at the end of reads only (\<4bp from read-end); this is no more than what we would have expected by chance, so we believe the read-end issue to be negligible.

*2) The authors claim that their analysis was unbiased and generated a catalogue of somatic mtDNA mutations. However, they excluded all candidate somatic mutations that recapitulated known mtDNA SNPs. The exclusion of SNPs is understood while considering the nuclear genome, however unlike the nuclear DNA the mtDNA molecule is in full linkage disequilibrium. This means that in order to avoid sample contamination the authors should exclude mutations in SNP positions ONLY when they phase along with other SNP mutations to form a haplotype*.

We did not exclude candidate somatic mutations which overlap with known mtDNA SNPs; instead our algorithm uses sequencing from the matched normal sample to exclude germline polymorphisms. For example, in our main manuscript, we state "Of these 1,907 somatic substitutions, 1,385 (72.6%) were not registered in the database of mtDNA common polymorphism (mtDB)". Thus, 27.4% of our mutations do overlap with previously known germline polymorphisms. Instead, we removed entire samples from the analysis when more than 3 of their somatic SNP candidates overlapped with known polymorphisms because such samples would be suggestive of cross-contamination with another sample, and lead to false mutation calls (see Materials and methods, Variant calling section, (3) Germline polymorphisms and back mutations). We would like to disclose that 66 samples (3.6%) were removed for this cross-contamination, out of the 1,848 samples initially enrolled in this study.

*3) The functional potential of mutations is not properly analyzed: dN/dS ratio calculated for genes does not reflect the functionality of specific mutations. Some estimation could be given by manipulations of this ratio using PAML or SELECTON. However the best way to assess the functional potential of variants is a comparison to disease causing mutations*.

We compared our mutation list with known disease-causing mtDNA mutations as the reviewer suggested. The results can be found in the [Supplementary file 2](#SD2-data){ref-type="supplementary-material"}. In addition, mutations more recurrent than expected are shown in [Supplementary file 5](#SD5-data){ref-type="supplementary-material"}. We have updated our manuscript accordingly.

Next, we assessed whether any specific somatic mutations showed evidence of positive selection. Out of the 1,907 somatic substitutions, 16 (0.8%) overlapped with known disease-associated mtDNA mutations, such as mutations frequently detected in MELAS (Mitochondrial Encephalomyopathy, lactic acidosis, and stroke-like episodes) and LHON (Leber hereditary optic neuropathy) ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). In addition, ten mutations within mitochondrial protein-coding, tRNA and rRNA genes showed significantly higher recurrent rate than expected from background mutational signature ([Supplementary file 5](#SD5-data){ref-type="supplementary-material"}). However, it remains unclear whether this high recurrence reflects positive selection, because any factors not included in our background model of the mutational process, such as local mutation hotspots, could also explain a mild excess of mutations at a given nucleotide.

However, we still think our approaches are appropriate. Below are our responses to the reviewer's concerns.

Point 1: The fraction of passenger mutations can be estimated from global dN/dS ratios

With respect to dN/dS ratio in detection of cancer genes, we have already shown that dN/dS measured at gene level is a powerful approach to identify driver genes (e.g. see Behjati et al, 2014 -PMID:24633157-, Bolli et al, 2014 -PMID:24429703- and Wong et al, 2014 -PMID: 24316979-). Of course, very subtle signals of selection, with infrequent positive selection acting at a single site, may escape this approach when applied to small datasets and a site-specific or codon-specific approach may be more powerful (see below).

Regarding our claim that most mutations are likely passenger events, we would like to highlight that the fraction of passenger mutations can indeed be estimated from gene or genome-level dN/dS ratios as long as negative selection is sufficiently weak. Here we have shown that, at least missense mutations seem to accumulate largely neutrally (see [Figure 5A](#fig5){ref-type="fig"}). Assuming that negative selection is absent, the fraction of driver mutations can be estimated using (w-1)/w, where w is the dN/dS ratio. This was explained in \[Greenman C., et al. 2006\]. If negative selection is stronger, this approach will provide an underestimation of the fraction of driver mutations.

Point 2: Use of PAML

We thank the referee for this interesting suggestion. We indeed considered and tried PAML. However, the assumptions of PAML are severely violated by this dataset leading to gross inaccuracies in the estimation of dN/dS. Critical assumptions that are violated are the simplistic mutation model (with a single rate parameter, the transition/transversion ratio), the assumption of strand symmetry (both strands mutate at very different rates), the reversibility of the mutation model (here we have an ancestral and a derived sequence, rather than two derived sequences) and potentially the stationarity of the sequence composition. To quantify the impact of these violations, we have performed simulations of neutral (randomly occurring) substitutions along the mitochondrial genome using the mutation spectrum described here (see [Figure 3A](#fig3){ref-type="fig"} or [Author response image 1](#fig6){ref-type="fig"} below). In particular, we simulated 600 random mutations per genome, allowing for multiple mutations occurring in the same site (which is a much higher density of mutations than we observe, and so situation is more favourable for PAML than for our Poisson-based method).Author response image 1.Somatic mutational signature of mitochondrial DNA

The resulting dN/dS estimates from 100 simulations are shown in [Author response image 2](#fig7){ref-type="fig"} below. This clearly shows that the simplistic mutation model used in PAML leads to severe and systematic inaccuracies in dN/dS (3rd box plot). A similar bias is seen in the traditional Nei-Gojobori model (Nei & Gojobori, 1986) (4th box plot). In contrast, accounting for the different rates of each trinucleotide and for the extreme strand asymmetry in mitochondrial mutations, our model leads to unbiased dN/dS estimates.Author response image 2.dN/dS ratio with 600 somatic substitutions randomly generated

Also, note that PAML cannot provide a dNon/dS ratio for nonsense mutation (nonsense mutations are excluded and a 61x61 codon substitution matrix is used).

Point 3: Selection at single-site level

Based on the simulations above, it is clear that PAML is not well suited to analyse this data reliably. The identification of highly recurrent sites within a protein should ideally take into consideration the exact sequence context of each site and the different mutation rates of each trinucleotide.

To address the referee\'s comments, we have extended our dN/dS approach to detect selection at single sites. Assuming a constant mutation spectrum across genes, we can test whether the level of site recurrence observed at each site violates the expected number of mutations given the local trinucleotide. A P-value can be computed for each site of a gene or a genome using a cumulative Poisson distribution (with lambda being the rate of the local trinucleotide), then correcting for multiple testing appropriately. This approach, which yields a p-value per site, is thus different from the Bayesian approach in PAML, being more similar to the method by Massingham and Goldman (2005, PMID: 15654091). Also note that this approach can be applied to non-coding sites as well as coding sites as it does not rely on a codon substitution matrix.

This analysis applied to our dataset revealed 10 sites within 37 mitochondrial genes (coding and non-coding) with a higher number of mutations than expected by neutral evolution assuming a constant mutation spectrum along the genome (shown in [Supplementary file 4](#SD4-data){ref-type="supplementary-material"}). It is, however, unclear whether the higher recurrence than expected reflects positive selection. Potential factors not considered in our statistical model, such as local mutation hotspots, may also explain these recurrences. It is worth noting that four of the recurrent sites are either synonymous or non-protein coding substitutions where positive selection is highly unlikely.

The analyses in this study suggest that most mutations in mitochondria are passenger events. We also did not find convincing evidence of driver events in any mitochondrial genes, using methods that have succeeded in finding known and novel cancer nuclear genes (see Behjati et al, 2014 -PMID:24633157-, Bolli et al, 2014 -PMID:24429703- and Wong et al, 2014 -PMID: 24316979-).

However, this does not rule out the possibility that a small fraction of mutations may be positively selected, too infrequently to be detected in the current dataset. We, however, found a list of recurrent hotspots whose origin and impact is unclear, that deserve further investigation.

[^1]: WGS, whole-genome sequencing; WXS, whole-exome sequencing; mt RD, mitochondrial read depth; MPD, myeloproliferative disease; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; CLL, chronic lymphoblastic leukemia; AML, acute myeloid leukemia; AMKL, acute megakaryoblastic leukemia.
